HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination

Adachi N, Kimura A, Horikoshi M . (2002). A conserved motif common to the histone acetyltransferase Esa1 and the histone deacetylase Rpd3. J Biol Chem 277: 35688–35695.

Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N et al. (2001). ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21: 6470–6483.

Amerik AY, Li SJ, Hochstrasser M . (2000). Analysis of the deubiquitinating enzymes of the yeast Saccharomyces cerevisiae. Biol Chem 381: 981–992.

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. (2005). Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729–26734.

Barlow AL, van Drunen CM, Johnson CA, Tweedie S, Bird A, Turner BM . (2001). dSIR2 and dHDAC6: two novel, inhibitor-resistant deacetylases in Drosophila melanogaster. Exp Cell Res 265: 90–103.

Bershadsky AD, Ballestrem C, Carramusa L, Zilberman Y, Gilquin B, Khochbin S et al. (2006). Assembly and mechanosensory function of focal adhesions: experiments and models. Eur J Cell Biol 85: 165–173.

Bertos NR, Gilquin B, Chan GK, Yen TJ, Khochbin S, Yang XJ . (2004). Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. J Biol Chem 279: 48246–48254.

Blagosklonny MV . (2002). Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16: 455–462.

Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, Meyer-Klaucke W et al. (2006). HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357–3366.

Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT et al. (2005). Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19: 1751–1759.

Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S . (2004). Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279: 7685–7691.

Cabrero JR, Serrador JM, Barreiro O, Mittelbrunn M, Naranjo-Suarez S, Martin-Cofreces N et al. (2006). Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell 17: 3435–3445.

Caron C, Boyault C, Khochbin S . (2005). Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27: 408–415.

Caron C, Col E, Khochbin S . (2003). The viral control of cellular acetylation signaling. Bioessays 25: 58–65.

Carta S, Tassi S, Semino C, Fossati G, Mascagni P, Dinarello CA et al. (2006). Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood 108: 1618–1626.

Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C et al. (2004). Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627–638.

Corcoran LJ, Mitchison TJ, Liu Q . (2004). A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr Biol 14: 488–492.

Destaing O, Saltel F, Gilquin B, Chabadel A, Khochbin S, Ory S et al. (2005). A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts. J Cell Sci 118: 2901–2911.

Dihazi H, Kessler R, Muller GA, Eschrich K . (2005). Lysine 3 acetylation regulates the phosphorylation of yeast 6-phosphofructo-2-kinase under hypo-osmotic stress. Biol Chem 386: 895–900.

Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O et al. (2003). Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 11: 139–150.

Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R et al. (2002). Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem 277: 6656–6666.

Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H et al. (2002). FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916–4921.

Gao L, Cueto MA, Asselbergs F, Atadja P . (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277: 25748–25755.

Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW et al. (2003). P300 transcriptional repression is mediated by SUMO modification. Mol Cell 11: 1043–1054.

Glozak MA, Sengupta N, Zhang X, Seto E . (2005). Acetylation and deacetylation of non-histone proteins. Gene 363: 15–23.

Goldberg AL, Cascio P, Saric T, Rock KL . (2002). The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39: 147–164.

Grozinger CM, Hassig CA, Schreiber SL . (1999). Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 96: 4868–4873.

Guardiola AR, Yao TP . (2002). Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277: 3350–3356.

Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS . (2004). Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079–1086.

Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL . (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100: 4389–4394.

Hallows WC, Lee S, Denu JM . (2006). Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA 103: 10230–10235.

Hayashi S, Yamaguchi Y . (2006). Basic research for hormone-sensitivity of breast cancer. Breast Cancer 13: 123–128.

Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102: 8567–8872.

Hook SS, Orian A, Cowley SM, Eisenman RN . (2002). Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci USA 99: 13425–13430.

Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al. (2002). HDAC6 is a microtubule-associated deacetylase. Nature 417: 455–458.

Hurst DR, Mehta A, Moore BP, Phadke PA, Meehan WJ, Accavitti MA et al. (2006). Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochem Biophys Res Commun 348: 1429–1435.

Iwabata H, Yoshida M, Komatsu Y . (2005). Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics 18: 4653–4664.

Iwata A, Riley BE, Johnston JA, Kopito RR . (2005). HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280: 40282–40292.

Kao HY, Lee CH, Komarov A, Han CC, Evans RM . (2002). Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J Biol Chem 277: 187–193.

Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP . (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727–738.

Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607–618.

Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J . (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019–2028.

Kouzarides T . (2000). Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176–1179.

Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. (2005). HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601–607.

Ling L, Lobie PE . (2004). RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription. J Biol Chem 279: 32737–32750.

Ma H, Nguyen C, Lee KS, Kahn M . (2005). Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24: 3619–3631.

Marcus AI, O’Brate A M, Buey RM, Zhou J, Thomas S, Khuri FR et al. (2006). Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res 66: 8838–8846.

Marcus AI, Zhou J, O’Brate A, Hamel E, Wong J, Nivens M et al. (2005). The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65: 3883–3893.

Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D et al. (2002). In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21: 6820–6831.

Mosley AJ, Meekings KN, McCarthy C, Shepherd D, Cerundolo V, Mazitschek R et al. (2006). Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. Blood 108: 3801–3807.

Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB . (2005). Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J Biol Chem 280: 33792–33799.

North BJ, Marshall BL, Borra MT, Denu JM, Verdin E . (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437–444.

Nusinzon I, Horvath CM . (2006). Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol 26: 3106–3113.

Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T . (2004). Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 112: 26–32.

Pantaloni D, Le Clainche C, Carlier MF . (2001). Mechanism of actin-based motility. Science 292: 1502–1506.

Pollard TD, Borisy GG . (2003). Cellular motility driven by assembly and disassembly of actin filaments. Cell 112: 453–465.

Pratt WB, Toft DO . (2003). Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111–133.

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P et al. (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1alpha. Cancer Res 66: 8814–8821.

Reed NA, Cai D, Blasius TL, Jih GT, Meyhofer E, Gaertig J et al. (2006). Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol 16: 2166–2172.

Romisch K . (2005). Endoplasmic reticulum-associated degradation. Annu Rev Cell Dev Biol 21: 435–456.

Rumpf S, Jentsch S . (2006). Functional division of substrate processing cofactors of the ubiquitin-selective Cdc48 chaperone. Mol Cell 21: 261–269.

Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S et al. (2005). Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24: 4531–4539.

Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T et al. (2006). Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29: 117–124.

Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E . (2006). Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA 103: 10224–10229.

Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K et al. (2007). An acetylation site in the middle domain of hsp90 regulates chaperone function. Mol Cell 25: 151–159.

Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S et al. (2001). Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 21: 8035–8044.

Serrador JM, Cabrero JR, Sancho D, Mittelbrunn M, Urzainqui A, Sanchez-Madrid F . (2004). HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 20: 417–428.

Shimazu T, Horinouchi S, Yoshida M . (2007). Multiple histone deacetylases and CBP regulates pre-mRNA 3′-end processing. J Biol Chem 282: 4470–4478.

Sterner DE, Berger SL . (2000). Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64: 435–459.

Tong JJ, Liu J, Bertos NR, Yang XJ . (2002). Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res 30: 1114–1123.

Valenzuela-Fernandez A, Alvarez S, Gordon-Alonso M, Barrero M, Ursa A, Cabrero JR et al. (2005). Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell 16: 5445–5454.

Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M et al. (2000). Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol 10: 747–749.

Verdel A, Khochbin S . (1999). Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. J Biol Chem 274: 2440–2445.

Wang Q, Song C, Li CC . (2003). Hexamerization of p97-VCP is promoted by ATP binding to the D1 domain and required for ATPase and biological activities. Biochem Biophys Res Commun 300: 253–260.

Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D et al. (2004). Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36: 377–381.

Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. (2002). Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 22: 7982–7992.

Yang XJ . (2004). Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 26: 1076–1087.

Yang XJ, Gregoire S . (2005). Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 25: 2873–2884.

Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M et al. (2004). Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 95: 496–502.

Zhang W, Kone BC . (2002). NF-kappaB inhibits transcription of the H(+)-K(+)-ATPase alpha(2)-subunit gene: role of histone deacetylases. Am J Physiol Renal Physiol 283: F904–F911.

Zhang Y, Gilquin B, Khochbin S, Matthias P . (2006). Two catalytic domains are required for protein deacetylation. J Biol Chem 281: 2401–2404.

Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S et al. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22: 1168–1179.

Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y et al. (2004). HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10: 6962–6968.

Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB et al. (2005). Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120: 715–727.

Zou H, Wu Y, Navre M, Sang BC . (2006). Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun 341: 45–50.